The partnership between Panbela and the University of Texas MD Anderson Cancer Center will focus on evaluating the combination of polyamine metabolic inhibitor therapy and CAR-T cell therapy. If successful, this research could lead to advancements in cancer treatment, which may positively impact Panbela's stock price in the short term.